Clinical Outcome for Patients with Metastatic Colorectal Cancer (mCRC) Enrolled in Phase I Clinical Trials: Single Institution Experience.

Santiago Aparo; Umang H. Shah; Gopichand Pendurti; Umang Swami; Yijuan Hou; Mohammad Haroon Ghalib; Imran Chaudhary; Sridhar Mani; Sanjay Goel

Clinical Outcome for Patients with Metastatic Colorectal Cancer (mCRC) Enrolled in Phase I Clinical Trials: Single Institution Experience.

Santiago Aparo, Umang H. Shah, Gopichand Pendurti, Umang Swami, Yijuan Hou, Mohammad Haroon Ghalib, Imran Chaudhary, Sridhar Mani, Sanjay Goel

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting
Volume	31
State	Published - 2013

Disciplines

Medicine and Health Sciences

Cite this

Clinical Outcome for Patients with Metastatic Colorectal Cancer (mCRC) Enrolled in Phase I Clinical Trials: Single Institution Experience. / Aparo, Santiago; Shah, Umang H.; Pendurti, Gopichand et al.
In: Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting, Vol. 31, 2013.

Research output: Contribution to journal › Article › peer-review

@article{cf4492363d60494ea7c3367a6fa9b36f,

title = "Clinical Outcome for Patients with Metastatic Colorectal Cancer (mCRC) Enrolled in Phase I Clinical Trials: Single Institution Experience.",

author = "Santiago Aparo and Shah, {Umang H.} and Gopichand Pendurti and Umang Swami and Yijuan Hou and Ghalib, {Mohammad Haroon} and Imran Chaudhary and Sridhar Mani and Sanjay Goel",

note = "e13550 Background: Phase I studies are a fundamental step in anti-cancer drug development. Prior meta-analysis looking at phase I studies showed an overall response rate (ORR) of 10.6 % and grade 4 toxicity rate of 14.3 %, and specifically, patients (pts) with mCRC enrolled in phase I trials had an ORR of 1.3 %.",

year = "2013",

language = "American English",

volume = "31",

journal = "Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting",

}

TY - JOUR

T1 - Clinical Outcome for Patients with Metastatic Colorectal Cancer (mCRC) Enrolled in Phase I Clinical Trials: Single Institution Experience.

AU - Aparo, Santiago

AU - Shah, Umang H.

AU - Pendurti, Gopichand

AU - Swami, Umang

AU - Hou, Yijuan

AU - Ghalib, Mohammad Haroon

AU - Chaudhary, Imran

AU - Mani, Sridhar

AU - Goel, Sanjay

N1 - e13550 Background: Phase I studies are a fundamental step in anti-cancer drug development. Prior meta-analysis looking at phase I studies showed an overall response rate (ORR) of 10.6 % and grade 4 toxicity rate of 14.3 %, and specifically, patients (pts) with mCRC enrolled in phase I trials had an ORR of 1.3 %.

PY - 2013

Y1 - 2013

UR - https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.e13550

M3 - Article

VL - 31

JO - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting

JF - Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting

ER -

Clinical Outcome for Patients with Metastatic Colorectal Cancer (mCRC) Enrolled in Phase I Clinical Trials: Single Institution Experience.

Disciplines

Other files and links

Cite this